EN DE
Watch Myomo Inc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Myomo Inc (MYO) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of Myomo Inc stock $1.15, price $1.27, that is 9.4% below the price, quality 31 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US

MI Myomo Inc logo Thin data Nov 10, 2026

Myomo Inc

MYO · US
Expensive, weak quality

Our calculation puts a fair price 9% below what the stock costs today.

Revenue last quarter +21% vs. a year ago.
Expensive Growth (revenue 5y +40.1 %/yr in USD)
Moderate debt
Insiders bought $317,748 (6M) · sold $181,391
Fair value $1.15 · Overvalued
Quality 31/100
Loss-making · -33.5% net margin (TTM)
Negative free cash flow
Trails peers (3/10)
Narrow moat 12/100
Thin data
Estimate
Watch Myomo Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$14.00 $0.4030 Fair Value $1.15 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

60‑month range $0.4030 – $14.00 · fair‑value band $0.8600 – $1.43 · the $1.27 price screens above the $1.15 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.

Follow Myomo in your weekly email

Every Wednesday you see whether Myomo is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Myomo, Inc., a wearable medical robotics company, designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States, Germany, and internationally.

Show moreShow less

The company offers MyoPro, a myoelectric-controlled upper limb brace or orthosis product used for supporting a patient's weak or paralyzed arm to enable and improve functional activities of daily living.

It also provides MyoPro 2 that includes control technology, configuration software and user interface, and pop-out battery for extended use of the brace; MyoPro2+, which comprises 3D printed orthotics capability, software enhancements, and a design for donning and doffing of the device; MyoGames, a virtual training platform; and MyoPro 2x Video Library.

In addition, the company offers MyoCare, a post-delivery program that provides follow-up care with clients, therapists, and referral sources; MYOMO; MyoPal; and MyoCoach.

Its products are designed to help adults and adolescents with neuromuscular conditions due to brachial plexus injury, stroke, traumatic brain injury, spinal cord injury, and other neurological disorders.

The company sells its products through various sales channels, including orthotics and prosthetics providers, veteran's administration, and distributors. Myomo, Inc. was incorporated in 2004 and is headquartered in Burlington, Massachusetts.

Stock analysis

Myomo Inc (MYO) currently trades at $1.27, while our estimate is $1.15, 9% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: $0.8600 (bear) to $1.43 (bull), the price of $1.27 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 31/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Myomo Inc reported revenue of $40.9M in FY2025 versus $13.9M in FY2021, a compound +31.1%/yr. Reported net income was −$15.6M in FY2025.

Key figures

Market cap $54.2M Micro · P/S ratio 1.11 · EPS (TTM) $−0.3500 · Net margin −33.5% · Return on equity −124% · Return on assets (EBIT) −52.9% (5-year average) · Operating margin −19.3% · Revenue (TTM) $43.3M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 12 out of 100 (medium confidence).

What moves the price

The share trades about 32% below its 52-week high and 98% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 8% fair-value upside, at −9%, MYO screens richer than that median.

Fair Value

Bear $0.8600 Fair Value $1.15 Bull $1.43
Price $1.27 · Downside -9.4%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 31/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 36
How much profit the company makes from its sales and capital
Quality Growth 40
Are margins and returns getting better?
Cashflow 10
Do the profits arrive as real cash?
Financial strength 45
Debt, balance sheet and risk of trouble
Investment 29
Does it invest with discipline instead of growing at any price?
Low Volatility 4
How calm the share price moves, does not count
Price momentum 75
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 70
Distance to the 52-week high, does not count
New shares 30
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, 2 officers or directors bought shares worth $317,748, most recently on Jun 5, 2026. Over the same period, 3 people sold shares worth $181,391. Buying cluster

  • SaleHarry KovelmanChief Medical Officer3× since May 27, 2026: 65,344 shares, avg. $1.26$82,642Sep 11, 2026
  • SaleMilton Mayo MorrisDirector15,000 shares at $1.41$21,150Sep 2, 2026
  • BuyThomas F KirkDirector5× since Nov 20, 2025: 219,445 shares, avg. $0.9127$200,283Jun 5, 2026
  • BuyJoseph M. Manko Jr.Director201,197 shares at $0.8645$173,940May 15, 2026
  • SaleMicah MitchellChief Commercial Officer90,231 shares at $0.8600$77,599May 14, 2026
  • BuyHeather C GetzDirector2× since Mar 12, 2026: 90,000 shares, avg. $0.7233$65,100Mar 16, 2026
  • BuyThomas Aloysius Crowley Jr.Director4,385 shares at $0.7335$3,216Nov 19, 2025

Plus 24 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 10, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 44/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+25.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+38.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+40.1%
Start year 2020 (pandemic). Over 10 years: +50.4% a year
Revenue growth 11 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+41.3%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−138.5% (2020) → −35.2% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

MYO screens overvalued: fair value 9% below the price. Compare with Abbott Laboratories, →

Compare Myomo Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 402 stocks

Beats the industry median on 3/9 measures
Overall it trails its industry peers.
Valuation
Quality Score 31 · Bottom 25%
Fair Value upside −9.4% · Above median
Profitability
Return on assets −40.3% · Bottom 25%
Net margin (12 months) −33.5% · Bottom 25%
Operating margin (12 months) −19.3% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 21.3% · Above median
Balance sheet
Debt / equity 0.98× · Highest 25%

Valuation Multiplesvs Medical Devices median · lower = cheaper

P/B 4.76× · Priciest 25%
P/S (12 months) 1.25× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)21 · sector 17
FUTURE (revenue growth)100 · sector 44
PAST (return on equity)0 · sector 0
HEALTH (low debt)51 · sector 97
DIVIDEND (yield)0 · sector 34

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Shenzhen Mindray Bio-Medical Electronics Co 300760 ¥178.92 ¥202.57 +13% vs MYO
DexCom, Inc DXCM $79.92 $89.18 +12% vs MYO
Stryker Corporation SYK $324.29 $358.30 +10% vs MYO
STERIS plc STE $257.12 $279.53 +9% vs MYO
Boston Scientific Corporation BSX $44.70 $48.42 +8% vs MYO
GE HealthCare Technologies Inc GEHC $83.65 $69.92 −16% vs MYO
Edwards Lifesciences Corporation EW $104.01 $81.94 −21% vs MYO
Abbott Laboratories, ABT $110.46 $75.28 −32% vs MYO
Medtronic plc MDT $101.59 $65.61 −35% vs MYO
Koninklijke Philips N.V PHIA €27.06 €15.23 −44% vs MYO

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Myomo Inc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Myomo Inc Fair Value". https://www.fairvalue-calculator.com/stock/MYO

Frequently asked questions

Is Myomo Inc (MYO) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is $1.15 versus a price of $1.27, about 9% lower (overvalued).
What is the fair value of MYO?
Our estimate for Myomo Inc is $1.15 (as of Nov 10, 2026), built from audited fundamentals. The current price: $1.27.
What is the quality score of MYO?
Myomo Inc has a Quality Score of 31/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Myomo Inc (MYO)?
Our calculated price target is the estimate of $1.15 (as of Nov 10, 2026). Cautious scenario $0.8600, optimistic scenario $1.43. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Myomo Inc stock forecast for 2026?
Our estimate puts fair value at $1.15, about 9% lower versus a price of $1.27 (overvalued). Cautious scenario $0.8600, optimistic scenario $1.43. The calculation is refreshed regularly with new filings.
What is the revenue of Myomo Inc (MYO)?
Myomo Inc reported trailing-twelve-month revenue of about $43.3M (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of Myomo Inc (MYO)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Myomo Inc it is $1.15 per share (as of Nov 10, 2026), against a price of $1.27.
Is Myomo Inc stock overvalued or undervalued in 2026?
As of Nov 10, 2026, MYO trades above its calculated fair value: price $1.27, fair value $1.15, a gap of about −9% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of MYO?
No. The price is what the market pays today ($1.27); the fair value is what the company's own numbers justify ($1.15). For Myomo Inc the two are $0.1200 per share apart. That gap is exactly why we show both numbers side by side.
How much is Myomo Inc worth?
The market values Myomo Inc at about $54.2M (market capitalisation, as of Nov 10, 2026). Per share that is $1.27; our models calculate a fair value of $1.15 per share.
What do the bullish and bearish scenarios say about MYO?
Our models span a range for Myomo Inc: cautious scenario $0.8600, base $1.15, optimistic $1.43 per share (as of Nov 10, 2026, price $1.27). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Myomo Inc (MYO)?
Balance-sheet figures for Myomo Inc (as of Nov 10, 2026): return on equity −123.8%, debt of 0.98 per unit of equity. They feed the Quality Score of 31/100, which measures business quality independently of the share price.
How far is MYO from its 52-week high?
Myomo Inc trades at $1.27, about 32% below its 52-week high of $1.86 and 98% above the low of $0.6400 (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of $1.15 is for.
Which stocks are comparable to Myomo Inc?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Myomo Inc stock attractive at the current price?
The data as of Nov 10, 2026: price $1.27, calculated fair value $1.15 (−9%), Quality Score 31/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. Myomo Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Myomo Inc (MYO)?
The closing price on Nov 10, 2026 was $1.27. Our estimate is $1.15, about 9% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Myomo Inc right now?
Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual. The price sits in the upper half of our model range, so the margin of safety is thin. Read the verdict with care: some models are missing inputs, so the estimate scatters more than usual.

Key figures of Myomo Inc

How large is the market capitalisation of Myomo Inc (MYO)?
The market capitalisation of Myomo Inc is $54.2M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Myomo Inc (MYO)?
The price-to-sales ratio of Myomo Inc is 1.11 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Myomo Inc (MYO)?
Earnings per share at Myomo Inc are $−0.3500. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Myomo Inc (MYO)?
The net margin of Myomo Inc is −33.5% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Myomo Inc (MYO)?
The return on equity (ROE) of Myomo Inc is −124% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Myomo Inc (MYO)?
On an EBIT basis the return on assets of Myomo Inc is −52.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Myomo Inc (MYO)?
The operating margin of Myomo Inc is −19.3% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Myomo Inc (MYO)?
Revenue at Myomo Inc is growing +21.3% versus a year earlier (3y avg +38.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Myomo Inc (MYO) generate?
The free cash flow of Myomo Inc is −$16.3M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Myomo Inc (MYO) carry?
The net debt of Myomo Inc is $5.3M (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Myomo Inc in the live analysis

One click puts Myomo Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.